Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | See Remarks | January 16, 2019 | January 18, 2019 |
| Attovia Therapeutics, Inc.ATTO · Entity 4984 | Chief Financial Officer | August 04, 2026 | October 09, 2026 |
| MyoKardia, Inc.MYOK · Entity 145206 | See Remarks | January 18, 2017 | January 20, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date January 16, 2019 · Filed January 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.36 · Expires 2029-01-15 | Direct | 35,000 |
Reported balance
After 2019-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-16 · Grant · Acquired 35,000 · Balance 35,000 F1: The option is exercisable in 48 equal monthly installments after January 16, 2019, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is exercisable in 48 equal monthly installments after January 16, 2019, subject to the Reporting Person's continued service to the Company.
Attovia Therapeutics, Inc.
Report date August 04, 2026 · Filed October 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-08-03 | Direct | 140,000 |
Reported balance
After 2026-08-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 140,000 · Balance 140,000 F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
MyoKardia, Inc.
Report date January 18, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.25 · Expires 2027-01-17 | Direct | 25,000 |
Reported balance
After 2017-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-18 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares underlying the option vest in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Oct 9, 2026 00:00 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001654907-26-000009 · form4a-10082026_111058.xml · derivative · entry 1 Chan Steven · CIK 0001654907 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-08-03 F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 18:25 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001209191-19-004497 · doc4.xml · derivative · entry 1 Chan Steven · CIK 0001654907 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-15 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 16, 2019, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 17:41 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0000899243-17-001669 · doc4.xml · derivative · entry 1 Chan Steven · CIK 0001654907 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2017, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| November 01, 2016 Filed Nov 2, 2016 17:41 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 2,041 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000899243-16-032642 · doc4.xml · derivative · entry 1 Chan Steven · CIK 0001654907 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,041 Underlying: Common Stock · 2,041 shares Expires 2025-06-03 F1 · balance_after: On June 4, 2015, the Reporting Person was granted an option to purchase 8,163 shares of Common Stock under the issuer's 2012 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On November 1, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 2,041 of the shares underlying such option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.